0
USD
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Hypercalcemia Drug"

Following a topic allows Research and Markets to customize your experience and provide personalized recommendations.
From
EUR$3,545USDGBP
EUR$3,939USDGBP
Hypercalcemia Treatment - Global Strategic Business Report - Product Thumbnail Image

Hypercalcemia Treatment - Global Strategic Business Report

  • Report
  • March 2025
  • 192 Pages
  • Global
From
EUR$4,950USDGBP
From
EUR$7,950USDGBP
Hypercalcemia - Epidemiology Forecast - 2032 - Product Thumbnail Image

Hypercalcemia - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
EUR$3,950USDGBP
  • 6 Results (Page 1 of 1)
Loading Indicator

Hypercalcemia is a condition in which the calcium levels in the blood are abnormally high. It is a common complication of hematological diseases, such as multiple myeloma and lymphoma. Treatment of hypercalcemia typically involves the use of drugs that reduce the absorption of calcium from the gut, increase its excretion from the body, or reduce its production in the bones. These drugs are known as hypercalcemia drugs and are used in combination with other treatments, such as hydration and diuretics. Hypercalcemia drugs are typically administered orally or intravenously, depending on the severity of the condition. Commonly used drugs include bisphosphonates, calcitonin, and calcimimetics. Bisphosphonates are the most commonly used drugs for hypercalcemia, as they reduce the absorption of calcium from the gut and increase its excretion from the body. Calcitonin is a hormone that helps reduce the production of calcium in the bones, while calcimimetics are drugs that act on the parathyroid glands to reduce the production of parathyroid hormone, which is responsible for increasing calcium levels in the blood. Some companies in the hypercalcemia drug market include Amgen, Novartis, Merck, and Eli Lilly. Show Less Read more

This website uses cookies to ensure you get the best experience. Learn more